Related Experiment Video
Updated: Nov 26, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller1, Martin van den Bent2, Matthias Preusser3
1Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. michael.weller@usz.ch.
Abstract:
In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.
Insights
Updated European Association of Neuro-Oncology (EANO) guidelines offer evidence-based recommendations for diagnosing and managing adult diffuse gliomas. These guidelines incorporate the latest molecular classifications and clinical trial data for optimal patient care.
Area of Science:
- Neuro-Oncology
- Clinical Neurology
- Cancer Research
Background:
- Evolving diagnostic criteria and clinical trial data necessitate updated guidelines for adult diffuse gliomas.
- Previous guidelines require revision to reflect current understanding and best practices in neuro-oncology.
Purpose of the Study:
- To provide updated, evidence-based guidelines for the diagnosis, treatment, and follow-up of adult patients with diffuse gliomas.
- To integrate the latest WHO classification and cIMPACT-NOW recommendations into clinical practice.
- To define the roles of surgery, radiotherapy, and pharmacotherapy in managing diffuse gliomas.
Main Methods:
- Development of guidelines by a European Association of Neuro-Oncology (EANO) task force.
- Evidence synthesis based on the 2016 WHO Classification of Tumors of the Central Nervous System and cIMPACT-NOW recommendations.
- Incorporation of results from recent practice-changing clinical trials.
Main Results:
- Recommendations for neuropathological and neuroradiological assessment are provided.
- The roles of surgery, radiotherapy, and systemic pharmacotherapy are clearly defined.
- Guidance emphasizes avoiding unnecessary interventions and expenses.
Conclusions:
- These guidelines serve as a comprehensive reference for healthcare professionals, patients, and caregivers managing adult diffuse gliomas.
- The updated recommendations aim to optimize diagnosis and treatment strategies based on current scientific evidence.
- Adherence to these guidelines can improve patient outcomes and healthcare resource utilization.
